After yesterday’s closing bell, BioMedical Technology Solutions Holdings, Inc. (OTCBB:BMTL) disclosed news that should put the company on radar this morning.  The company, which has a market cap of only $873,000 and closed yesterday at 2.6 cents per share, has received a $13.1 million order for its Demolizer II units and Collectors from a distributor in Recife, Brazil including customer orders from the Government agencies of ADAGRO and LACEN.  The first batch of the environmentally-friendly biomedical waste disposal units are slated to be delivered within 90 days with the remainder shipping over the next 12 to 18 months.

The company expects to have a profitable 2012 based on this one order alone, according to its press release.

The revolutionary Demolizer® II system uses a heating process (no chemicals at all) to render biomedical waste sterile so it may be discarded with common trash, saving on expensive trucking fees and all the subsequent environmental pollutants related to legacy processes to dispose of biomedical waste.  It provides automatic generation of state and federal compliance documentation. The system meets or exceeds all Environmental Protection Agency and Centers for Disease Control guidelines and is approved/meets treatment requirements in 48 states after having been reviewed by 80 governmental agencies.

BioMedical Technology Solutions rents and sells the Demolizer®II in the U.S. and internationally.

“This order is the culmination of a year-long effort in Brazil. Brazil is a great market for us and this is just the tip of the iceberg for international sales,” said Gex “Jay” F. Richardson, President and Chairman of BMTS Holdings, Inc.  “We are systematically entering other international markets and receiving great success in each market we enter and anticipate more announcements soon.”

BioMedical Technology Solutions Holdings (BMTL) Stock Quote and News:

---

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article, but holds shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.